This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.

Inclusion Criteria:

• Subjects with T2DM (Type 2 Diabetes Mellitus), including newly-diagnosed subjects, who require treatment with Victoza® according to the clinical judgment of their treating physician
• Subjects (and/or parents or the subject's legally acceptable representative) who are capable of giving study-specific signed informed consent before any collection of information

Exclusion Criteria:

• Subjects with a hypersensitivity to Victoza® or to any of the excipients
• Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods
• Subjects with personal or family history of medullary thyroid carcinoma (MTC)
• Subjects with multiple endocrine neoplasia syndrome type 2 (MEN2)

Victoza® will be prescribed and titrated by the physician.